Related Experiment Video
Updated: Feb 20, 2026
A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
Published on: September 26, 2011
AG488 as a therapy against gliomas
Jadith Ziegler1,2, Anja Bastian3, Megan Lerner4
1Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Abstract:
High-grade gliomas such as glioblastomas (GBM) present a deadly prognosis following diagnosis and very few effective treatment options. Here, we investigate if the small molecule AG488 can be an effective therapy against GBM with both anti-angiogenic as well as an anti-microtubule inhibiting modalities, using a human G55 glioma xenograft model in nude mice. From in vitro studies, we report that AG488 incubation reduced cell viability in G55 and HMEC-1 cells more so than TMZ treatment, and AG488 treatment also decreased cell viability in normal astrocytes, but not as much as for G55 cells (p<0.0001). In vivo investigations indicated that AG488 therapy helped reduce tumor volumes (p<0.0001), prolong survival (p<0.01), increase tumor perfusion (p<0.01), and decrease microvessel density (MVD) (p<0.05), compared to untreated mice or mice treated with non-specific IgG, in the G55 xenograft model. Additionally, AG488 did not induce apoptosis in normal mouse brain tissue. Animal survival and tumor volume changes for AG488 were comparable to TMZ or anti-VEGF therapies, however AG488 was found to be more effective in decreasing tumor-related vascularity (perfusion and MVD). AG488 is a potential novel therapy against high-grade gliomas.
Insights
The small molecule AG488 shows promise as a novel therapy for high-grade gliomas. It effectively reduced glioblastoma cell viability and tumor growth in preclinical models with anti-angiogenic and anti-microtubule effects.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Pharmacology
Background:
- High-grade gliomas, including glioblastomas (GBM), have a poor prognosis and limited treatment options.
- Novel therapeutic strategies are urgently needed to improve outcomes for GBM patients.
Purpose of the Study:
- To investigate the efficacy of the small molecule AG488 as a potential therapy for glioblastoma.
- To evaluate AG488's anti-angiogenic and anti-microtubule inhibitory effects against GBM.
Main Methods:
- In vitro studies using G55 glioma and HMEC-1 cells, as well as normal astrocytes.
- In vivo investigations utilizing a human G55 glioma xenograft model in nude mice.
- Assessment of cell viability, tumor volume, animal survival, tumor perfusion, and microvessel density (MVD).
Main Results:
- AG488 significantly reduced G55 and HMEC-1 cell viability more than temozolomide (TMZ) in vitro.
- In vivo, AG488 decreased tumor volumes, prolonged survival, increased tumor perfusion, and reduced MVD.
- AG488 demonstrated comparable efficacy to TMZ or anti-VEGF therapies but was more effective in reducing tumor vascularity.
Conclusions:
- AG488 exhibits potent anti-cancer activity against high-grade gliomas through dual mechanisms.
- AG488 represents a potential novel therapeutic agent for glioblastoma treatment.
- Further clinical investigation of AG488 for high-grade gliomas is warranted.
